Boehringer Ingelheim’s experimental pill has shown signs of improving kidney function in patients with a rare renal condition in a mid-stage trial. But the data are somewhat confusing, with the lowest dose working better than …
Sanofi vows to stay committed to vaccines as portfolio takes a hit
Sanofi CEO Paul Hudson emphasized the company’s commitment to vaccine development in the face of an increasingly challenging sales environment and its decision to abandon


